Velafermin

Summary

Velafermin is a recombinant human fibroblast growth factor‑20 (FGF‑20) analog under investigation for the prevention and treatment of oral and gastrointestinal mucositis associated with cancer therapy. It is administered intravenously as a protein drug and has been evaluated in pre‑clinical animal models and a phase I safety trial in patients undergoing high‑dose chemotherapy and autologous stem‑cell transplant.

Mechanism of Action

Velafermin belongs to the fibroblast growth factor family and stimulates epithelial cell proliferation and tissue repair. In animal studies it reduced inflammatory cytokines such as interleukin‑6 and tumor necrosis factor, likely through modulation of the NF‑κB pathway, and increased expression of the antioxidant regulator NRF‑2, contributing to mucosal protection and faster healing after chemoradiation injury.

What the Research Shows

Pre‑clinical work shows that velafermin mitigates chemotherapy‑induced gastrointestinal mucositis in rats, decreasing diarrhea incidence, delaying onset, and lowering mortality when given at 16 mg/kg before irinotecan. In a hamster model of fractionated radiation‑induced oral mucositis, intraperitoneal dosing (4 mg/kg) reduced lesion severity, improved histology, and lowered IL‑6, TNF, and NF‑κB activity while raising NRF‑2 expression. A phase I open‑label dose‑escalation study in 30 patients receiving high‑dose chemotherapy and autologous PBSCT reported tolerability up to 0.2 mg/kg IV, with no drug‑related serious adverse events. Higher doses (0.33 mg/kg) caused immediate infusion reactions. No efficacy data from controlled human trials have been published; phase II studies were initiated but results remain unpublished.

Reported Benefits

Animal investigations suggest that velafermin can lessen the severity and duration of both chemotherapy‑ and radiation‑induced mucositis, improve epithelial integrity, and reduce inflammatory mediator production. In humans, early-phase safety data indicate the drug can be administered intravenously without serious toxicity at doses up to 0.2 mg/kg, supporting its potential for further efficacy testing.

Limitations of the Evidence

Evidence of therapeutic benefit is currently limited to rodent and hamster models; human data are confined to a small, uncontrolled phase I safety trial that did not assess mucositis outcomes. No peer‑reviewed results from the announced phase II trials are available, and the optimal dosing schedule remains undefined. Consequently, efficacy and comparative advantage over existing supportive care measures remain unproven.

Safety Considerations

Velafermin was well tolerated in the phase I study at doses up to 0.2 mg/kg IV, with no drug‑related serious adverse events. The most common treatment‑emergent adverse events (≥35% of participants) were mild to moderate diarrhea, fatigue, fever, vomiting, and nausea, all resolving the same day. Two participants receiving 0.33 mg/kg experienced immediate infusion reactions, prompting cessation of dose escalation. No long‑term safety data are available.

How It Is Administered

The investigational product is a recombinant protein administered intravenously, typically as a single infusion over 15 minutes in clinical studies. Pre‑clinical work employed intraperitoneal injection in rodents, but human trials have used the IV route. Formulation details beyond the protein nature are not disclosed in the literature.

Routes of Administration

Goals & Uses

• Prevention of oral mucositisOncology Supportive CareModerate
• Gastrointestinal mucosal healingMucosal RegenerationLow
• Reduction of chemotherapy-induced mucosal toxicityOncology Supportive CareModerate

Contraindications

• Active malignancy with FGF receptor-driven tumor growthOncologicModerate
• Known hypersensitivity to FGF analogs or E. coli-derived proteinsAllergy / ImmunologicHigh

Adverse Effects

• Fever / PyrexiaSystemicUncommon
• Hypersensitivity / allergic reactionImmunologicalRare
• Injection site reactionsLocalCommon
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit

Drug Interactions

• High-dose chemotherapy agents (busulfan, cyclophosphamide)Low

Population Constraints

• Pediatric patientsAgeRelative
• Pregnant or lactating womenReproductiveRelative
• Patients with active FGF receptor-driven malignanciesOncologicRelative

Regulatory Status

• European UnionUnknownNo EMA approval or marketing authorization known; no public EMA review record identified.
• United StatesInvestigationalEvaluated in FDA IND-phase clinical trials for oral mucositis in HSCT; no NDA filed or approved.
• United KingdomUnknownNo MHRA approval identified; development appears inactive.

Velafermin has not received FDA, EMA, or MHRA approval. It was evaluated in Phase II clinical trials for oral mucositis prevention in HSCT patients. Development appeared to stall after mixed clinical trial results; no approved indication exists in any major jurisdiction.

Evidence & Sources

• Gateways to clinical trials. July-August 2008
  Journal ArticleLowTomillero A, Moral MA2008-01-01T00:00:00.000000Z
• Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats
  Journal ArticleLowGibson RJ, et al.2007-01-01T00:00:00.000000Z
• Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant
  Journal ArticleModerateSchuster MW, et al.2008-01-01T00:00:00.000000Z
• Gateways to clinical trials
  Journal ArticleLowBayés M, Rabasseda X, Prous JR2007-01-01T00:00:00.000000Z
• Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation
  Journal ArticleLowAra G, et al.2008-01-01T00:00:00.000000Z
• Velafermin (CuraGen)
  Journal ArticleLowLalla RV2005-01-01T00:00:00.000000Z

Frequently Asked Questions